Objective Systemic lupus is a chronic autoimmune disease characterised by its phenotypic heterogeneity. Neutropaenia is a frequent event in SLE occurring in 20%–40% of patients depending on the ...
Objective To investigate the effects of Qihuang Jianpi Zishen Granules (QJZG) on renal injury in SLE mice, focusing on macrophage M1/M2 polarisation mediated by the AMPK/ULK1 signalling pathway.
Objective Corticosteroids are a mainstay of SLE treatment; however, cumulative steroid exposure may lead to organ damage. This study aimed to quantify the risk of new diabetes, hypertension, cataracts ...
Objectives X chromosome has been considered as a risk factor for SLE, which is a prototype of autoimmune diseases with a significant sex difference (female:male ratio is around 9:1). Our study aimed ...
Background Emerging evidences indicate that a distinct CD11c+T-bet+ B cell subset termed age/autoimmune-associated B cells (ABCs) is the major pathogenic autoantibody producer in lupus. Human lupus is ...
Objective We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included ...
Objective SLE is a complex, heterogenous autoimmune disease. SLE researchers do not always collect the same data, making comparative studies difficult. We aimed to ascertain what variables SLE ...
Objectives Up 50% of pregnancies in women with systemic lupus erythematosus (SLE) is complicated by adverse outcomes, such as preterm birth, fetal growth restriction and pre-eclampsia. The underlying ...
Objectives The 2023 EULAR recommendations for the management of SLE endorse stratifying disease activity into mild, moderate, and severe categories to guide treat-to-target (T2T) strategies. Both ...
Objectives To define a fit-for-purpose clinical outcome assessment, and thresholds for entry and improvement, for the serositis domain of a multi-domain outcome measure for clinical trials in systemic ...
Objectives To characterise the clinical presentation, laboratory findings, treatment approaches, and outcomes of systemic lupus erythematosus (SLE)-associated macrophage activation syndrome (MAS), and ...
Objectives Emerging therapies such as CAR-T-cells have been reported to induce deeper B-cell depletion and thereby drug-free remission up to 24 months. Anecdotally, we observed ‘RTX super-responders’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results